Abstract ▼
, Munich, Germany), using arachidonic acid (ASPI: 0.5 mM), TRAP-6 (TRAP: 32 uM), collagen (3.2 ug), ADP (6.5 uM) and Ristocetin (Risto: 0.77 mg / ml) in isotonic saline prediluted (0.3 ml) hirudin-anticoagulated (25 ug / ml) whole blood (1.3 or 5 ml tubes). Aggregation was continuously recorded over fi ve minutes. The increase of impedance due to the attachment of platelets to the electrodes was detected and transformed separately to arbitrary aggregation units [ Introduction ▼ Primary haemostasis involves a controlled cascade of events where under fl ow conditions activated platelets play a key role. Vascular damage induces the interaction with collagen, and von Willebrand factor leading to platelet activation, which then through release of numerous activation propagates, i. e. platelet adhesion to the vascular tissue, platelet aggregation, and formation of a platelet plug. Apart from acquired platelet function disorders, which in the majority of cases are due to administration of antiplatelet agents or antibiotics, inherited disorders of platelets constitute a group of rare diseases that give rise to bleeding syndromes of variety severity also observed during infancy and childhood [2, 12] . Monitoring antiplatelet therapy or diagnosis of a platelet function disorder is based on the observation of abnormalities of the patient ' s platelets as compared to normal platelets [2, 4, 5, 12, 13] . In the past, platelet function was assessed mainly for platelet haemostatic capacity to control bleeding. The physiologically closest way to test platelet function is the bleeding time by inducing a lesion and to measure the time required to stop bleeding. A standardized method to test the bleeding time has been developed using a template for the injury of the microvasculature tissue with a defi ned length and depth of the cut [9] . This method was widely used in the last decade but is not very popular today and in children because it hurts, leaves scars and is not very sensitive and specifi c. Another in vitro method, the light transmission aggregometry, in which agonists can be added to platelet rich plasma and then increase the light transmission when platelets start to aggregate was fi rst described by Born in the early 60 th [3] . This method still known as the gold standard, has also a variety of limitations such as the need to separate platelets from other cell components. However, none of the tests reported including the " gold standard " are suitable for clinical practice, where a simple instrument enabling quick measurement of platelet function with minimal volume of blood is needed. Thus, to appropriate diagnose a platelet function disorder in a point-of-care setting during early childhood or to monitor antiplatelet agents in children the knowledge of the physiological characteristics of platelets in the paediatric population is mandatory [5 -8, 1 -12] . The newly developed point-of-care instrument [14] , the Multiplate analyzer (Dynabyte ® , Munich, Germany) permits platelet aggregation to be measured after adding commonly used agonists by detecting changes in electrical resistance in small volumes of whole blood: Since paediatric reference values for this promising method are missing, the aim of the present study was to establish reference values in healthy infants and children.
Methods

▼ Ethics, patients and control subjects
The present study was performed in accordance with the ethical standards laid down in the updated version of the 1964 Declaration of Helsinki and was approved by the medical ethics committee of the University of M ü nster, Germany. With written parental consent, 265 healthy term neonates and children were enrolled. Control children had no history of chronic diseases and were not on medication at the time of recruitment. They presented as outpatients for evaluation prior to minor surgery (planned circumcisions and hernias > 90 % ) or potential bone marrow donations ( ~ 10 % ]. Blood cell counts of the healthy children enrolled were within the normal age-dependent reference ranges reported for children in our institutions (150 000 / ul -350 000 / ul for platelet count). In addition, with parental consent aggregation curves of two paediatric patients with known Glanzmann ' s thrombasthenia are shown. Genetic sequencing was done in the CHU Robert Debre in Paris [Nicole Schlegel].
Exclusion criteria
Children with underlying medical conditions including obesity [defi ned as body mass index > 30 kgm − 2 ] and infants, children and adolescents with a personal or family bleeding history or new laboratory evidence of an inherited or acquired plasmatic coagulation disorder, such as von Willebrand disease, were not enrolled in the present study.
Blood sample collection
Blood sample collection was done in the morning after a 12 h fasting period (infants 4 -6 h); whole blood samples were drawn by peripheral venipuncture into 1.3 or 5 ml plastic tubes, containing hirudin (25 ug / ml) as anticoagulant. The blood was kept at room temperature during the experiment.
Measuring platelet aggregation
Aggregation was assessed on the Multiplate analyzer (Dynabyte ® , Munich, Germany), using adenosine diphosphate . Based on literature data controls were divided into four age groups: 0.1 -12 months, 1.1 -4 years, 5 -9 years, and 10 -< 18 years. Diff erences in baseline data between age groups were analysed after log-transformed data using one-way analysis of variance and Student-Newman-Keuls post hoc test for all pairwise comparisons. A p-value < 0.05 was considered statistically signifi cant.
Results ▼ • ▶ Fig. 1a - 
Discussion ▼
Patients with hereditary platelet function defects display haemorrhagic patterns much like thrombocytopenic bleeding. Bleeding manifestations, however, may be severe or mild depending on the underlying defect. Although exceptions are known, the more severe the specifi c defect, the worse the bleeding tendency is detected. Since the mid 1960s platelet aggregation testing has been the mainstay used to diagnose and classify hereditary platelet function disorders in patients in whom von Willebrand disease or further plasmatic bleeding disorders have been exclu- ded [1, 16] . With careful attention to technical details, the aggregation curves produced by various agonists provide a sensitive method of detection of most the underlying patho-mechanisms: the patterns of abnormalities in the aggregation curves can be used to tentatively classify the underlying disease. Classical aggregometry is performed in platelet rich plasma prepared by centrifugation of anticoagulated blood in specialized laboratories only. Apart from its poor standardization across laboratories, a major limitation of the classical aggregometric methods for routine use in a paediatric population is that these techniques are consuming much more plasma, i. e. up to 20 ml when performing the complete testing. Technically, whole blood systems are advantageous because they do not require preparation of platelets. Thus, any whole blood systems test not platelets alone, but also their interaction with the other cells in blood. This approach appears to be closer to physiological conditions, and is easier to handle. Therefore, the aim of the present study was to establish paediatric reference values as a prerequisite for future clinical studies for this whole blood point-of-care device. This is the fi rst study evaluating the point-of-care Multiplate ® whole blood aggregometry in healthy children. This method is independent on platelet concentration [when platelets are within the normal range], and had an analytical time window between 30 and 240 min after blood sample collection [14] . In addition, the anticoagulant hirudin used in the sample collection tubes has the advantage of preserving the physiological concentration of ionised calcium and magnesium, and thus prevents clotting by inhibiting the action of thrombin. In contrast, the commonly used sodium citrate induces platelet Ca + + fl ux. Therefore, blood anticoagulated with sodium citrate should rest after collection that platelets could recover [4] . A further advantage of this method allows the clinician to use small amounts of whole blood (1.3 -5 ml) to discriminate between severe inherited platelet function disorders and normal platelet function, as shown exemplarily for the two patients with Glanzmann ' s thrombasthenia. Although we have shown the usefulness of whole blood impedance aggregometry to discriminate between normal platelet function and Glanzmann ' s thrombasthenia in children, we further have to clarify the role of this point-of-care instrument in diagnosing other inherited or acquired platelet function disorders like Bernard-Soulier-Syndrome, or aspirin therapy in children with stroke. In addition, due to the small number of infants enrolled further infants within the fi rst year of life have to be enrolled to obtain robust references values in this specifi c age group. Especially for the paediatric stroke population this approach seems to be very promising: as shown and discussed before by Riess in 1986 and VelikSalchner and coworkers results of this method were no diff erent from those obtained with classical aggregometry for detecting the eff ects of aspirin and clopidogrel in adult preoperative patients scheduled for elective surgery [15, 17] . Keeping in mind that there is no single best method currently available the correct diagnosis of inherited platelet function disorders cannot be performed alone by aggregation studies in platelet rich plasma or whole blood, and requires additional tools such as fl ow-cytometry and molecular diagnosis, further multicentre studies are mandatory to get a feasible consensus for the step by step diagnostic strategy on inherited and / or acquired platelet function disorders in children. 
